



261 Mountain View Dr
 Colchester, VT 05446
 License #: TLAB0030
 802-767-7256
 info@onwardanalytics.biz

Certificate of Analysis

Client Name: Vermont Kind
License Number: SCLT0186 MANU0027

Sample ID: VT16490
Sample Name: Anthomancer Virgin Extract
Sample Lot: MANU0027-C0076
Sample Matrix: Solvent Extraction Concentrates
Date Received: 12/11/2024
Date Reported: 12/19/2024
Date Tested: 12/16/2024



| Total Cannabinoids | | |
|----------------------------|---------------|----------------|
| | % | mg/g |
| Total THC: | 70.130 | 701.299 |
| Total CBD: | -- | -- |
| Total Cannabinoids: | 76.119 | 761.190 |

Total theoretical CBD % = (CBD%) + (CBDA% * 0.877)
Total theoretical THC % = (delta-9-THC%) + (THCA% * 0.877)

Potency

Standard potency analysis utilizing High Performance Liquid Chromatography (HPLC; SOP-024-OA) | Test ID: #53242

| Analyte | % | mg/g | LOD (mg/g) | LOQ (mg/g) |
|---------|---------|---------|------------|------------|
| CBC | 1.0366 | 10.366 | 0.0003 | 0.0040 |
| CBCA | < LOQ | < LOQ | 0.0002 | 0.0040 |
| CBD | < LOQ | < LOQ | 0.0008 | 0.0040 |
| CBDA | ND | ND | 0.0002 | 0.0040 |
| CBDV | ND | ND | 0.0008 | 0.0040 |
| CBDVA | ND | ND | 0.0001 | 0.0040 |
| CBG | 2.5064 | 25.064 | 0.0009 | 0.0040 |
| CBGA | < LOQ | < LOQ | 0.0001 | 0.0040 |
| CBN | 0.8531 | 8.531 | 0.0004 | 0.0040 |
| CBNA | ND | ND | 0.0002 | 0.0040 |
| D8 THC | ND | ND | 0.0012 | 0.0040 |
| D9 THC | 66.2879 | 662.879 | 0.0016 | 0.0049 |
| D10 THC | ND | ND | 0.0004 | 0.0040 |
| THCA | 4.3808 | 43.808 | 0.0002 | 0.0040 |
| THCV | 1.0542 | 10.542 | 0.0016 | 0.0049 |
| THCVA | ND | ND | 0.0002 | 0.0040 |

Callie Chapman
 Lab Director
 12/19/2024

In performing the services, Onward Analytics, ("OA") shall exercise a degree of skill and care ordinarily exercised by a reasonably prudent laboratory professional under similar circumstances. Except as set forth in the preceding sentence, client acknowledges and agrees that: (a) the services may require OA to make judgements based upon limited data rather than upon scientific certainties; (b) OA's approach, recommendations, and associated cost estimates, if any, are based on industry practices and averages; (c) OA renders its opinions with respect to observations made and data available at the time of testing; (d) ultimate outcomes could be inconsistent with OA's conclusions, results and projections; and (e) there may be additional reports relating to the site (whether prepared by OA or other parties), and reliance upon any OA report without reference to any such other reports is done at client's sole risk.

